Sarepta Therapeutics,, Inc. Common Stock | SRPT

Daily Technical Analysis of Sarepta Therapeutics,, Inc. Common Stock

Sarepta Therapeutics hasn't moved too much today but is slightly down, it has lost -0.74% since yesterday. It looks like SRPT may be interacting with an upward sloping support line. These can create nice entry points since it can have both momentum and support. SRPT hasn't established a very clear directional momentum over the last few months. So it's not clear if it has the energy to break through or not.

If we get a reversal off of support and Sarepta Therapeutics starts moving up, it can probably get to $157.19 at which point it'll need to break through that resistance level in order to keep moving higher. There aren't very obvious support levels beneath this point. So put those stop losses on, this thing has room to fall if buyers don't come in at this level.

Analyst Ratings for Sarepta Therapeutics By Price Target And Rating

The analysts feel pretty optimistic about Sarepta Therapeutics and have been assigning positive ratings. The current Analysts Sentiment Score is 249.30. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. Oppenheimer announced a lowering of their price target to $150.00 from $180.00 on 2023-03-09. JPMorgan Chase & Co. provided a price target boost of 34.64% to $206.00 from $153.00 on 2023-03-03. On 2023-03-01 Barclays increased their price target by 14.09% to $170.00. On 2023-03-01 Morgan Stanley upgraded Sarepta Therapeutics from Equal Weight to Overweight and moved up their price target to $187.00 which is a 32.62% increase. On 2023-03-01 The Goldman Sachs Group increased their price target by 11.11% to $190.00. On 2023-03-01 Credit Suisse Group increased their price target by 5.11% to $144.00. Robert W. Baird provided a price target boost of 32.89% to $202.00 from $152.00 on 2023-03-01. Royal Bank of Canada gave a boost to their price target and moved to $226.00 from $195.00 on 2023-03-01. Needham & Company LLC boosted their price targ by 25% to $200.00 on 2023-03-01. On 2023-01-20 there was confirmation of the previous rating by SVB Leerink which was Outperform and they set their price target at $160.00.

Earnings Per Share (EPS) Estimates By Year and Quarter

Short interest for Sarepta Therapeutics

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Social Sentiment for Sarepta Therapeutics

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.